Precigen, Inc. (PGEN)
Nasdaq · Healthcare · Biotechnology
$7.74−9.37%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.8B
- 52-week range
- $2.99 – $8.98
- 52-week change
- +158.01%
- EPS (trailing)
- −$1.04
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $9.7M (+146.73%)
- Net income
- −$251M
- Operating margin
- −1141.2%
- Diluted EPS
- −$1.37
- Free cash flow
- −$89.8M
From the company’s annual report on SEC EDGAR.
About Precigen, Inc.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
Headquarters: Germantown, United States · 160 employees · precigen.com